A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/00 (2006.01) A61K 35/76 (2006.01) A61K 38/27 (2006.01) A61K 48/00 (2006.01) A61P 21/00 (2006.01) A61P 25/00 (2006.01) A61P 25/14 (2006.01) A61P 43/00 (2006.01)
Patent
CA 2649820
Disclosed is a therapeutic agent for polyglutamine disease or an inhibitor of the development of polyglutamine disease, which comprises, as an active ingredient, the following component (1) or (2): (1) (i) an HGF protein or (ii) a peptide which is a partial peptide of the HGF protein and which has substantially the same activities as those of the HGF protein, or a salt thereof; or (2) DNA comprising (i) DNA encoding the HGF protein, (ii) DNA encoding a peptide which is a partial peptide of the HGF protein and which has substantially the same activities as those of the HGF protein, or (iii) DNA which can hybridize with DNA having a nucleotide sequence complementary to that of the DNA (i) or (ii) under stringent conditions and which encodes a protein or peptide having substantially the same activities as those of the HGF protein.
L'invention concerne un agent thérapeutique destiné à traiter les maladies à polyglutamine ou un inhibiteur du développement de ces maladies, cet agent ou cet inhibiteur comprenant, comme ingrédient actif, le composant (1) ou (2) suivant: (1) (i) une protéine du HGF ou (ii) un peptide qui est un peptide partiel de la protéine du HGF et qui a sensiblement les mêmes activités que celles de la protéine du HGF, ou un sel de celui-ci; ou (2) un ADN comprenant (i) l'ADN codant la protéine du HGF; (ii) l'ADN codant un peptide qui est un peptide partiel de la protéine du HGF et qui a sensiblement les mêmes activités que celles de la protéine du HGF ou (iii) l'ADN qui peut s'hybrider à l'ADN ayant une séquence nucléotidique complémentaire à celle de l'ADN (i) ou (ii) dans des conditions rigoureuses et qui code une protéine ou un peptide ayant sensiblement les mêmes activités que celles de la protéine du HGF.
Funakoshi Hiroshi
Iwatani Kunio
Miyazawa Daisuke
Nakamura Toshikazu
Kringle Pharma Inc.
Osaka University
Torys Llp
LandOfFree
Agent for treating polyglutamine aggregation-caused disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for treating polyglutamine aggregation-caused disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for treating polyglutamine aggregation-caused disease... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1826847